No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 26 of the 40 quarters in the window, leaving 14 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 1.3x · 10Y median 0.8x · 68th percentile · as of Sep 9, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:02:04.959Z. Latest historical point 2026-09-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for InMed Pharmaceuticals Inc. (INM) stock was $1.34 as of Oct 6, 2026, 9:47 AM EDT, up 0.93% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -41.8% · 3-year avg -53.9%/yr · 5-year avg -72.0%/yr
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids.
Drug Manufacturers - Specialty & Generic · Vancouver, BC
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-94.44
Revenue Est.
$300000.00
Last Quarter Results
EPS
$-1.43
vs Estimate
$-94.44
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1INM | $7.37M | $1.34 | +0.93% | -41.77% | -71.98% | -52.81% | N/A |
| 2LGVN | $7.46M | $2.45 | -2.39% | -67.97% | -62.60% | N/A | vs INM |
| 3HSCS | $7.49M | $3.47 | -20.47% | +17.75% | N/A | N/A | vs INM |
| 4KALA | $7.25M | $0.37 | +3.42% | -99.52% | -85.73% | N/A | vs INM |
| 5MGRX | $7.18M | $0.42 | +1.20% | -81.44% | N/A | N/A | vs INM |
| 6CURX | $7.17M | $5.06 | +2.02% | -68.03% | N/A | N/A | vs INM |
forward FY estimate
N/A
$2.06B
vs Estimate
$2.06B
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$1.34
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-94.44 | $-94.44 | $-94.44 | 1 |
| Quarter ending Dec 2026 | $-135.47 | $-135.47 | $-135.47 | 1 |
| Quarter ending Mar 2027 | $-175.00 | $-175.00 | $-175.00 | 1 |
| Quarter ending Jun 2027 | $-117.50 | $-117.50 | $-117.50 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $300000.00 | $300000.00 | $300000.00 | 1 |
| Quarter ending Dec 2026 | $300000.00 | $300000.00 | $300000.00 | 1 |
| Quarter ending Mar 2027 | $300000.00 | $300000.00 | $300000.00 | 1 |
| Quarter ending Jun 2027 | $125000.00 | $125000.00 | $125000.00 | 1 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
